CL2019002190A1 - Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984) - Google Patents

Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)

Info

Publication number
CL2019002190A1
CL2019002190A1 CL2019002190A CL2019002190A CL2019002190A1 CL 2019002190 A1 CL2019002190 A1 CL 2019002190A1 CL 2019002190 A CL2019002190 A CL 2019002190A CL 2019002190 A CL2019002190 A CL 2019002190A CL 2019002190 A1 CL2019002190 A1 CL 2019002190A1
Authority
CL
Chile
Prior art keywords
therapeutic protein
viscosity
concentration
antibody
reduction
Prior art date
Application number
CL2019002190A
Other languages
English (en)
Inventor
Christopher James Sloey
Sekhar Kanapuram
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54427875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019002190(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2019002190A1 publication Critical patent/CL2019002190A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Abstract

SE PROPORCIONA UN MÉTODO PARA REDUCIR LA VISCOSIDAD DE UNA FORMULACIÓN FARMACÉUTICA QUE UTILIZA UNA CONCENTRACIÓN DE REDUCCIÓN DE LA VISCOSIDAD DE UN EXCIPIENTE SELECCIONADO DEL GRUPO QUE CONSISTE DE LA N-ACETIL ARGININA, N-ACETIL LISINA, N-ACETIL PROLINA Y MEZCLAS DE LOS MISMOS EN COMBINACIÓN CON UNA PROTEÍNA TERAPÉUTICA. TAMBIÉN SE PROPORCIONA UNA FORMULACIÓN FARMACÉUTICA ESTABLE.
CL2019002190A 2014-10-23 2019-08-02 Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984) CL2019002190A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462067637P 2014-10-23 2014-10-23

Publications (1)

Publication Number Publication Date
CL2019002190A1 true CL2019002190A1 (es) 2019-11-22

Family

ID=54427875

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017000984A CL2017000984A1 (es) 2014-10-23 2017-04-20 Reducción de la viscosidad de formulaciones farmacéuticas
CL2019002190A CL2019002190A1 (es) 2014-10-23 2019-08-02 Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2017000984A CL2017000984A1 (es) 2014-10-23 2017-04-20 Reducción de la viscosidad de formulaciones farmacéuticas

Country Status (17)

Country Link
US (2) US11813328B2 (es)
EP (2) EP3209332B1 (es)
JP (3) JP2017531682A (es)
KR (1) KR102534017B1 (es)
CN (2) CN114569716A (es)
AU (2) AU2015335743B2 (es)
BR (1) BR112017008125B1 (es)
CA (1) CA2964786C (es)
CL (2) CL2017000984A1 (es)
EA (3) EA202191513A1 (es)
ES (1) ES2964713T3 (es)
IL (2) IL287947B1 (es)
MA (1) MA54716A (es)
MX (2) MX2017005243A (es)
SG (1) SG11201703152RA (es)
WO (1) WO2016065181A1 (es)
ZA (1) ZA201702762B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202191513A1 (ru) 2014-10-23 2021-11-30 Эмджен Инк. Снижение вязкости фармацевтических составов
JP7275027B2 (ja) * 2016-10-06 2023-05-17 アムジェン インコーポレイテッド 粘度低下タンパク質医薬製剤
JP7377596B2 (ja) * 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
EP3615065A1 (en) 2017-04-28 2020-03-04 Amgen Inc. Excipients to reduce the viscosity of antibody formulations and formulation compositions
AU2018258676A1 (en) 2017-04-28 2019-10-31 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
EP3624846A1 (en) 2017-05-16 2020-03-25 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
CN110996988A (zh) * 2017-09-22 2020-04-10 旭化成制药株式会社 稳定性优异的含有特立帕肽的液态药物组合物
WO2019106206A1 (en) 2017-12-01 2019-06-06 Fyb 202 Project Gmbh Stable, low viscosity, high concentration liquid formulations of an anti-il-12/23p40 antibody
BR112020026492A2 (pt) 2018-07-05 2021-04-06 Bayer Aktiengesellschaft Método para a produção de péletes liofilizados compreendendo um anticorpo antifator de coagulação xia (fxia)
EP3628683A1 (en) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
CA3141857A1 (en) * 2019-04-23 2020-10-29 Amgen Inc. The use of low molecular weight polyvinylpyrrolidone (pvp) to reduce viscosity of high concentration protein formulations

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078997A (en) 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
US6767892B1 (en) * 1997-11-07 2004-07-27 Chrion Corporation Compositions providing for increased IGF-I solubility
AU1519399A (en) * 1997-11-07 1999-05-31 Chiron Corporation Compositions providing for increased igf-i solubility
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6159485A (en) * 1999-01-08 2000-12-12 Yugenic Limited Partnership N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use
AU4458401A (en) 2000-03-31 2001-10-15 Kirin Brewery Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability
EP1343518B1 (en) 2000-11-07 2009-07-22 Novartis Vaccines and Diagnostics, Inc. Stabilized interferon compositions
SI1425389T1 (sl) 2001-08-23 2012-02-29 Genmab As Humana protitelesa, specifična za interlevkin 15 (IL-15)
JP4583762B2 (ja) 2002-02-27 2010-11-17 イミュネックス・コーポレーション ポリペプチド製剤
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
CA2512174A1 (en) 2003-01-30 2004-08-12 Christian B. Allan Anti-integrin .alpha..nu..beta.3 antibody formulations and uses thereof
PL2335725T3 (pl) * 2003-04-04 2017-04-28 Genentech, Inc. Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
CA2589860A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
EP1977763A4 (en) * 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd STABILIZER PREPARATION CONTAINING ANTIBODIES
CN101426527A (zh) * 2006-02-03 2009-05-06 米迪缪尼有限公司 蛋白质制剂
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
AU2007249349B2 (en) 2006-05-11 2012-03-08 Isis Pharmaceuticals, Inc. 5'-Modified bicyclic nucleic acid analogs
AU2007334499B2 (en) 2006-12-14 2014-04-24 Merck Sharp & Dohme Corp. Engineered anti-TSLP antibody
KR20100034015A (ko) 2007-06-20 2010-03-31 아이알엠 엘엘씨 알레르기 질환 치료를 위한 방법 및 조성물
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
KR20190045414A (ko) * 2007-11-30 2019-05-02 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
WO2009090189A1 (en) * 2008-01-15 2009-07-23 Abbott Gmbh & Co.Kg Powdered protein compositions and methods of making same
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
JP2011067202A (ja) * 2009-08-31 2011-04-07 Sanyo Chem Ind Ltd タンパク質水溶液の安定化剤、この安定化剤を含有するタンパク質水溶液及びタンパク質の安定化方法
EP2501367B1 (en) * 2009-11-17 2015-01-21 Ipsen Pharma S.A.S. Formulation for HGH and RHIGF-1 combination
AU2011212440B2 (en) 2010-02-04 2015-01-22 Csl Behring Ag Immunoglobulin preparation
EP3409289B1 (en) * 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
WO2011109415A2 (en) 2010-03-02 2011-09-09 Amgen Inc. Reducing viscosity of pharmaceutical formulations
MX2012012743A (es) * 2010-05-03 2012-11-23 Genentech Inc Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
AU2012328524B2 (en) * 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
EP2863951A1 (en) 2012-06-12 2015-04-29 Boehringer Ingelheim International GmbH Pharmaceutical formulation for a therapeutic antibody
US20150004174A1 (en) 2013-06-28 2015-01-01 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
TWI694836B (zh) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
EA202191513A1 (ru) 2014-10-23 2021-11-30 Эмджен Инк. Снижение вязкости фармацевтических составов
RU2748841C2 (ru) 2014-12-03 2021-05-31 Цсл Беринг Аг Фармацевтический продукт с увеличенной стабильностью, содержащий иммуноглобулины
MX2019003727A (es) 2016-09-29 2019-08-05 Amgen Inc Proteinas de union a antigeno de baja viscosidad y metodos de prepararlas.
JP7275027B2 (ja) 2016-10-06 2023-05-17 アムジェン インコーポレイテッド 粘度低下タンパク質医薬製剤
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法

Also Published As

Publication number Publication date
ES2964713T3 (es) 2024-04-09
EA202191513A1 (ru) 2021-11-30
CN107206070A (zh) 2017-09-26
SG11201703152RA (en) 2017-05-30
US20240066124A1 (en) 2024-02-29
US11813328B2 (en) 2023-11-14
ZA201702762B (en) 2022-12-21
BR112017008125B1 (pt) 2023-11-21
EA038462B1 (ru) 2021-08-31
CA2964786C (en) 2023-10-17
JP2017531682A (ja) 2017-10-26
EA201991447A1 (ru) 2019-11-29
MX2017005243A (es) 2017-08-18
CN107206070B (zh) 2022-01-18
EA201790787A1 (ru) 2017-08-31
BR112017008125A2 (pt) 2018-06-19
AU2015335743B2 (en) 2020-12-24
IL287947A (en) 2022-01-01
AU2021200990A1 (en) 2021-03-11
EA033444B1 (ru) 2019-10-31
JP7411615B2 (ja) 2024-01-11
CN114569716A (zh) 2022-06-03
EP3909611A1 (en) 2021-11-17
US20170333559A1 (en) 2017-11-23
JP6965321B2 (ja) 2021-11-10
IL251726B (en) 2021-12-01
JP2022009223A (ja) 2022-01-14
MA54716A (fr) 2021-11-17
IL251726A0 (en) 2017-06-29
EP3209332B1 (en) 2021-05-26
JP2020037559A (ja) 2020-03-12
WO2016065181A1 (en) 2016-04-28
CL2017000984A1 (es) 2018-01-05
AU2021200990B2 (en) 2023-02-16
MX2021015789A (es) 2022-01-27
KR20170071518A (ko) 2017-06-23
CA2964786A1 (en) 2016-04-28
EP3909611B1 (en) 2023-08-30
IL287947B1 (en) 2024-04-01
EP3209332A1 (en) 2017-08-30
AU2015335743A1 (en) 2017-05-04
KR102534017B1 (ko) 2023-05-19

Similar Documents

Publication Publication Date Title
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
ES2965722T3 (es) Compuestos excipientes reductores de la viscosidad para formulaciones proteicas
CL2019000431A1 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. (divisional solicitud 201700814)
CL2016002148A1 (es) Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos.
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CR20150228A (es) Inhibidores de la tirosina-quinasa de bruton
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
CR20160203A (es) Inhibidores de tirosina cinasa de bruton
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
EA201692292A1 (ru) Соединения и композиции для стимулирования хондрогенеза
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
CL2015002692A1 (es) Novedosos compuestos de bencenosulfonamida, método para sintetizarlos y uso de los compuestos en medicina y en cosméticos.
AR098168A1 (es) Formulación estable de insulina glulisina
ECSP14023048A (es) Agentes terapéuticos para administración subcutánea optimizados
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
EA201990093A1 (ru) Двухкомпонентная композиция
EA201892157A1 (ru) Фосфаплатиновые жидкие составы
BR112015028302A2 (pt) formulação de pastilha de nicotina
BR112018004244A2 (pt) formulações sólidas de pirofosfato férrico solúvel, kits e seus métodos de uso